CT/MRI Co-Registration Prostate Cancer
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The target volume in prostate cancer radiotherapy typically consists of the entire prostate gland which is localized by contours drawn on axial computed tomography (CT) radiation planning images. Compared with CT, magnetic resonance (MR) can provide better definition of the prostate gland with respect to the surrounding tissues and the use of multi-plannar reconstruction avoids the problem of partial volume averaging inherent in CT. CT has been shown to significantly overestimate the volume of the gland using the MR-defined prostate volume as the gold standard. Co-registration of MR and CT datasets, matched on fixed bony landmarks, has enabled radiation planning using a MR-defined clinical target volumes, combined with CT-based electron density information necessary for radiation treatment planning.
Rationale and Hypothesis:
Co-registration may allow better delineation of tumour volumes in prostate cancer. This investigation is a fesibility study designed to evaluate and optimize imaging parameters and co-registration techniques for CT planning and MRI Simulator.
| Condition | Intervention | Phase |
|---|---|---|
|
Prostatic Neoplasm |
Device: Computed Tomography Scan and Magnetic Resonance Imaging |
Phase 1 |
| Study Type: | Observational |
| Study Design: | Observational Model: Defined Population Primary Purpose: Screening Time Perspective: Cross-Sectional Time Perspective: Prospective |
| Official Title: | Evaluation of Planning Computed Tomography Scan and Magnetic Resonance Imaging Simulator Scan Co-Registration for Delineation of Gross Tumour Volume in Radiotherapy Treatment of Localized Prostate Cancer |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histological confirmation of Prostate Adenocarcinoma
- Undergoing RT with fiducial markers, IMRT or Escalated Dose Conformal RT
Exclusion Criteria:
- Contraindication for MRI
Contacts and Locations| Canada, Ontario | |
| University Health Network | |
| Toronto, Ontario, Canada, M5G 2M9 | |
| Principal Investigator: | Andrew Bayley, MD | Princess Margaret Hospital, Canada |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00252460 History of Changes |
| Other Study ID Numbers: | UHN REB 03-0601-CE |
| Study First Received: | November 9, 2005 |
| Last Updated: | November 9, 2005 |
| Health Authority: | Canada: Ethics Review Committee |
Additional relevant MeSH terms:
|
Neoplasms Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms |
Neoplasms by Site Genital Diseases, Male Prostatic Diseases |
ClinicalTrials.gov processed this record on May 22, 2013